Literature DB >> 19549909

Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance.

Denada Dibra1, Jeffry J Cutrera, Xueqing Xia, Mark P Birkenbach, Shulin Li.   

Abstract

It is well known that the interleukin (IL)-27 receptor WSX1 is expressed in immune cells and induces an IL-27-dependent immune response. Opposing this conventional dogma, this study reveals a much higher level of WSX1 expression in multiple types of epithelial tumor cells when compared with normal epithelial cells. Expression of exogenous WSX1 in epithelial tumor cells suppresses tumorigenicity in vitro and inhibits tumor growth in vivo. Different from the role of WSX1 in immune cells, the antitumor activity of WSX1 in epithelial tumor cells is independent of IL-27 signaling but is mainly dependent on natural killer (NK) cell surveillance. Deficiency of either the IL-27 subunit EBV-induced gene 3 or the IL-27 receptor WSX1 in the host animals had no effect on tumor growth inhibition induced by WSX1 expression in tumor cells. Expression of WSX1 in epithelial tumor cells enhances NK cell cytolytic activity against tumor cells, whereas the absence of functional NK cells impairs the WSX1-mediated inhibition of epithelial tumor growth. The underlying mechanism by which WSX1 expression in tumor cells enhances NK cytolytic activity is dependent on up-regulation of NKG2D ligand expression. Our results reveal an IL-27-independent function of WSX1: sensitizing NK cell-mediated antitumor surveillance via a NKG2D-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549909      PMCID: PMC2706921          DOI: 10.1158/0008-5472.CAN-08-4311

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates.

Authors:  Luzheng Liu; Ann Chahroudi; Guido Silvestri; Mary E Wernett; William J Kaiser; Jeffrey T Safrit; Akira Komoriya; John D Altman; Beverly Z Packard; Mark B Feinberg
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

2.  Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment.

Authors:  Atsunobu Takeda; Shinjiro Hamano; Atsushi Yamanaka; Toshikatsu Hanada; Tatsuro Ishibashi; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

3.  Costimulation of multiple NK cell activation receptors by NKG2D.

Authors:  Emily L Ho; Leonidas N Carayannopoulos; Jennifer Poursine-Laurent; Jeremy Kinder; Beatrice Plougastel; Hamish R C Smith; Wayne M Yokoyama
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

4.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Authors:  Daniela Pende; Paola Rivera; Stefania Marcenaro; Chien-Chung Chang; Roberto Biassoni; Romana Conte; Marek Kubin; David Cosman; Soldano Ferrone; Lorenzo Moretta; Alessandro Moretta
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

5.  WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.

Authors:  A K Bednarek; C L Keck-Waggoner; R L Daniel; K J Laflin; P L Bergsagel; K Kiguchi; A J Brenner; C M Aldaz
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

6.  Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.

Authors:  Yoshihiro Hayakawa; Janice M Kelly; Jennifer A Westwood; Phillip K Darcy; Andreas Diefenbach; David Raulet; Mark J Smyth
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

7.  Distinct requirements for IFNs and STAT1 in NK cell function.

Authors:  C K Lee; D T Rao; R Gertner; R Gimeno; A B Frey; D E Levy
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

8.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

9.  Antiproliferative activity of IL-27 on melanoma.

Authors:  Takayuki Yoshimoto; Noriko Morishima; Izuru Mizoguchi; Motomu Shimizu; Hiroshi Nagai; Shuntaro Oniki; Masahiro Oka; Chikako Nishigori; Junichiro Mizuguchi
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

10.  Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance.

Authors:  Arun M Unni; Tanya Bondar; Ruslan Medzhitov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-25       Impact factor: 11.205

View more
  16 in total

1.  Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30.

Authors:  Denada Dibra; Jeffry J Cutrera; Shulin Li
Journal:  J Immunol       Date:  2012-03-09       Impact factor: 5.422

Review 2.  IL-27: a double agent in the IL-6 family.

Authors:  G W Jones; D G Hill; A Cardus; S A Jones
Journal:  Clin Exp Immunol       Date:  2018-03-09       Impact factor: 4.330

Review 3.  Modulation of inflammation by interleukin-27.

Authors:  Markus Bosmann; Peter A Ward
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

4.  Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions.

Authors:  Jeffry Cutrera; Glenn King; Pamela Jones; Kristin Kicenuik; Elias Gumpel; Xueqing Xia; Shulin Li
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 5.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

6.  Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.

Authors:  Denada Dibra; Abhisek Mitra; Melisa Newman; Xueqing Xia; Jeffry J Cutrera; Mihai Gagea; Eugenie S Kleinerman; Guillermina Lozano; Shulin Li
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

7.  Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice.

Authors:  Denada Dibra; Xueqing Xia; Abhisek Mitra; Jeffry J Cutrera; Guillermina Lozano; Shulin Li
Journal:  Hepatology       Date:  2016-01-21       Impact factor: 17.425

8.  WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.

Authors:  Man Wu; Xueqing Xia; Jiemiao Hu; Natalie Wall Fowlkes; Shulin Li
Journal:  Nat Commun       Date:  2021-06-09       Impact factor: 14.919

9.  WSX1 expression in tumors induces immune tolerance via suppression of effector immune cells.

Authors:  Denada Dibra; Jeffry Cutrera; Xueqing Xia; Shulin Li
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.

Authors:  Hyangsoon Noh; Jiemiao Hu; Xiaohong Wang; Xueqing Xia; Arun Satelli; Shulin Li
Journal:  Cell Commun Signal       Date:  2015-02-27       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.